129 related articles for article (PubMed ID: 35438962)
1. Molecular Basis of the Recognition of Cholesterol by Cytochrome P450 46A1 along the Major Access Tunnel.
Shi N; Zheng Q; Zhang H
ACS Chem Neurosci; 2022 May; 13(10):1526-1533. PubMed ID: 35438962
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Dicaffeoylspermidine Derivatives from Wolfberry as Potent and Selective Inhibitors of Human Cytochrome P450 46A1
Du J; Liu J; Wang S; Wang C; Meng Q; Sun H; Liu K; Liu Y; Wu J
Curr Drug Metab; 2023; 24(2):124-130. PubMed ID: 36748817
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Petrov AM; Pikuleva IA
Neurotherapeutics; 2019 Jul; 16(3):635-648. PubMed ID: 31001737
[TBL] [Abstract][Full Text] [Related]
4. Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.
Anderson KW; Mast N; Hudgens JW; Lin JB; Turko IV; Pikuleva IA
J Biol Chem; 2016 May; 291(22):11876-86. PubMed ID: 27056331
[TBL] [Abstract][Full Text] [Related]
5.
Mast N; Anderson KW; Johnson KM; Phan TTN; Guengerich FP; Pikuleva IA
J Biol Chem; 2017 Aug; 292(31):12934-12946. PubMed ID: 28642370
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.
Mast N; White MA; Bjorkhem I; Johnson EF; Stout CD; Pikuleva IA
Proc Natl Acad Sci U S A; 2008 Jul; 105(28):9546-51. PubMed ID: 18621681
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
Mast N; Verwilst P; Wilkey CJ; Guengerich FP; Pikuleva IA
J Med Chem; 2020 Jun; 63(12):6477-6488. PubMed ID: 31617715
[TBL] [Abstract][Full Text] [Related]
8. New Therapeutic Targets for Brain Function and Disease.
van Lier JE
J Med Chem; 2020 Jun; 63(12):6474-6476. PubMed ID: 31845585
[TBL] [Abstract][Full Text] [Related]
9. CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease.
Lerner AJ; Arnold SE; Maxfield E; Koenig A; Toth ME; Fortin B; Mast N; Trombetta BA; Denker J; Pieper AA; Tatsuoka C; Raghupathy S; Pikuleva IA
Alzheimers Res Ther; 2022 Dec; 14(1):198. PubMed ID: 36581878
[TBL] [Abstract][Full Text] [Related]
10. Brain sterol flux mediated by cytochrome P450 46A1 affects membrane properties and membrane-dependent processes.
Petrov AM; Mast N; Li Y; Denker J; Pikuleva IA
Brain Commun; 2020; 2(1):. PubMed ID: 32661514
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
Mast N; Lin JB; Anderson KW; Bjorkhem I; Pikuleva IA
PLoS One; 2017; 12(10):e0187168. PubMed ID: 29073233
[TBL] [Abstract][Full Text] [Related]
12. CYP46A1-dependent and independent effects of efavirenz treatment.
Mast N; El-Darzi N; Petrov AM; Li Y; Pikuleva IA
Brain Commun; 2020; 2(2):fcaa180. PubMed ID: 33305262
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond.
Moutinho M; Nunes MJ; Rodrigues E
Biochim Biophys Acta; 2016 Dec; 1861(12 Pt A):1911-1920. PubMed ID: 27663182
[TBL] [Abstract][Full Text] [Related]
14. In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.
Mast N; Linger M; Clark M; Wiseman J; Stout CD; Pikuleva IA
Mol Pharmacol; 2012 Nov; 82(5):824-34. PubMed ID: 22859721
[TBL] [Abstract][Full Text] [Related]
15. The potential of CYP46A1 as a novel therapeutic target for neurological disorders: An updated review of mechanisms.
Alavi MS; Karimi G; Ghanimi HA; Roohbakhsh A
Eur J Pharmacol; 2023 Jun; 949():175726. PubMed ID: 37062503
[TBL] [Abstract][Full Text] [Related]
16. Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response.
Mast N; Zheng W; Stout CD; Pikuleva IA
J Biol Chem; 2013 Feb; 288(7):4613-24. PubMed ID: 23288837
[TBL] [Abstract][Full Text] [Related]
17. Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux.
Mast N; Petrov AM; Prendergast E; Bederman I; Pikuleva IA
Neurotherapeutics; 2021 Jul; 18(3):2040-2060. PubMed ID: 34235635
[TBL] [Abstract][Full Text] [Related]
18. The Hydroxylation Position Rather than Chirality Determines How Efavirenz Metabolites Activate Cytochrome P450 46A1 In Vitro.
Mast N; Fotinich A; Pikuleva IA
Drug Metab Dispos; 2022 Jul; 50(7):923-930. PubMed ID: 35489779
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.
Mast N; Li Y; Linger M; Clark M; Wiseman J; Pikuleva IA
J Biol Chem; 2014 Feb; 289(6):3529-38. PubMed ID: 24352658
[TBL] [Abstract][Full Text] [Related]
20. Unbiased insights into the multiplicity of the CYP46A1 brain effects in 5XFAD mice treated with low dose-efavirenz.
Mast N; Butts M; Pikuleva IA
J Lipid Res; 2024 Jun; 65(6):100555. PubMed ID: 38719151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]